Alzamend Neuro (NASDAQ:ALZN) Price Target Lowered to $20.00 at Ascendiant Capital Markets

Alzamend Neuro (NASDAQ:ALZN) had its price objective reduced by Ascendiant Capital Markets from $32.00 to $20.00 in a research report issued to clients and investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock.

Alzamend Neuro Stock Down 1.8 %

Shares of ALZN opened at $0.68 on Monday. Alzamend Neuro has a 12-month low of $0.64 and a 12-month high of $15.06. The stock’s fifty day simple moving average is $1.02 and its 200-day simple moving average is $1.36.

Alzamend Neuro (NASDAQ:ALZN) last posted its earnings results on Monday, March 10th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.10. As a group, sell-side analysts predict that Alzamend Neuro will post -1.68 EPS for the current year.

Hedge Funds Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Geode Capital Management LLC purchased a new position in shares of Alzamend Neuro, Inc. (NASDAQ:ALZN) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 33,540 shares of the company’s stock, valued at approximately $39,000. Geode Capital Management LLC owned approximately 0.62% of Alzamend Neuro at the end of the most recent reporting period. 49.61% of the stock is owned by institutional investors.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.